男人宫殿

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

---------------


F O R M 8 - K/A


CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d)
OF THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported) October 31, 1997
----------------------------

Cytoclonal Pharmaceutics Inc.
- ------------------------------------------------------------------------------
(Exact name of Registrant as Specified in Charter)


Delaware 0-26918 75-2402409
- ------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission) (IRS Employer
of Incorporation) File Number) Identification No.)


9000 Harry Hines Boulevard, Suite 330, Dallas, Texas 75235
- ------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)


Registrant's telephone number, including area code (214) 353-2922
--------------------------


N/A
- ------------------------------------------------------------------------------
(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS.

During October 1997, Cytoclonal Pharmaceutics Inc. (the "Company") raised
approximately $1,196,000 from the exercise of stock options and warrants. The
following Balance Sheet, Statement of Operations (unaudited) and Statements
of Changes in Stockholders' Equity (unaudited) of Cytoclonal Pharmaceutics
Inc. for the month ended October 31, 1997 reflect the operations of the
Company including proceeds from the stock option and warrant exercises.



2

CYTOCLONAL PHARMACEUTICS INC.
(a development stage company)

BALANCE SHEET

October 31,
1997
(unaudited)
-----------
ASSETS

Current assets:

Cash $ 2,143,000
Prepaid expenses and other current assets 16,000
------------

Total current assets 2,159,000

Equipment, net 104,000

Patent rights, less accumulated amortization
of $450,000 800,000

Other assets 4,000
------------

T O T A L $ 3,067,000
------------
------------


LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:

Accounts payable and accrued expenses $ 347,000

Current portion of royalties payable 70,000
------------

Total current liabilities 417,000

Royalties payable less current portion 1,156,000
------------

Total liabilities 1,573,000
------------

Stockholders' equity:
Preferred stock - $.01 par value, 10,000,000
shares authorized; 999,944 shares of Series A
convertible preferred issued and outstanding
at October 31, 1997 (liquidation value
$2,500,000 at October 31, 1997) 10,000

Common Stock - $.01 par value, 30,000,000
shares authorized; 8,672,061 shares issued
and outstanding at October 31, 1997 87,000

Additional paid-in capital 15,972,000

Deficit accumulated during the development stage (14,575,000)
------------

Total Stockholders' Equity 1,494,000
------------

T O T A L $ 3,067,000
------------
------------

3



CYTOCLONAL PHARMACEUTICS INC.
(a development stage company)

STATEMENT OF OPERATIONS
(unaudited)

One Month Ended
October 31, 1997
----------------
Operating expenses

Research and development 112,000
General and administrative 154,000
---------
266,000
---------
Other (income) expenses
Interest (income) (5,000)
Interest expense 0
---------
(5,000)
NET (LOSS) ($261,000)
---------
---------

4

CYTOCLONAL PHARMACEUTICS INC.
(a development stage company)

STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(unaudited)